Related Experiment Video

Updated: Jul 30, 2026

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
06:02

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Published on: July 26, 2011

Platycodigenin as Potential Drug Candidate for Alzheimer's Disease via Modulating Microglial Polarization and Neurite

Zhiyou Yang1,2, Baiping Liu3, Long-En Yang4

  • 1College of Food Science and Technology, Guangdong Provincial Key Laboratory of Aquatic Product Processing and Safety, Institute of nutrition and marine drugs, Guangdong Ocean University, Zhanjiang 524088, China. yang_zhiyou@sina.com.

Molecules (Basel, Switzerland)
|September 7, 2019
PubMed

Insights

Platycodigenin, a natural compound, shifts microglia towards an anti-inflammatory state, reducing neuroinflammation and promoting neuronal survival. This offers a potential therapeutic avenue for Alzheimer's disease (AD) by targeting the brain's microenvironment.

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Neuroinflammation is central to Alzheimer's disease (AD) pathogenesis, influencing neurite regrowth and neuronal survival.
  • Microglia, the brain's immune cells, polarize into M1 (pro-inflammatory) or M2 (anti-inflammatory) phenotypes, impacting the neuroinflammatory microenvironment.
  • Targeting microglia polarization and promoting neurite regeneration are potential therapeutic strategies for AD.

Purpose of the Study:

  • To investigate the effects of platycodigenin, a natural triterpenoid, on microglia polarization and its therapeutic potential in Alzheimer's disease.
  • To determine if platycodigenin can modulate neuroinflammation and promote neuronal health in AD models.

Main Methods:

  • Utilized lipopolysaccharide (LPS)-stimulated BV2 and primary microglia to assess platycodigenin's impact on M1/M2 polarization.
  • Quantified pro-inflammatory (IL-1β, TNF-α, IL-6, NO, Cox2) and anti-inflammatory (IL-10, Ym1/2) markers.
  • Examined the effects on signaling pathways including MAPK p38, NF-κB, and PPARγ.
  • Assessed platycodigenin's efficacy in promoting neurite regeneration and neuronal survival in primary cortical neurons treated with Aβ.

Main Results:

  • Platycodigenin promoted M2 microglia polarization while inhibiting M1 polarization.
  • It downregulated key pro-inflammatory mediators (IL-1β, TNF-α, IL-6, NO, Cox2) and upregulated the anti-inflammatory cytokine IL-10.
  • Platycodigenin reduced LPS-induced hyperphosphorylation of MAPK p38 and NF-κB p65, and ameliorated LPS-induced PPARγ inactivation.
  • Significantly promoted neurite regeneration and neuronal survival in primary cortical neurons exposed to Aβ.

Conclusions:

  • Platycodigenin effectively ameliorates neuroinflammation by modulating microglia polarization towards an M2 phenotype.
  • It protects neurons from Aβ-induced damage by reducing inflammation and promoting neurite regeneration and survival.
  • Platycodigenin represents a promising therapeutic candidate for Alzheimer's disease.
Keywords:
PPARγmicroglial polarizationneurite regenerationplatycodigenin

More Related Videos

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons06:23

Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons

Published on: October 30, 2018

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...